28 studies found for:    Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate OR Stribild[TREATMENT] AND HIV [CONDITION]
Show Display Options
Download search resultsDownload the search results for:
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate OR Stribild[TREATMENT] AND HIV [CONDITION] (28 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Intervention: Drug: EVG/COBI/FTC/TDF
2 Active, not recruiting Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: Placebo to match E/C/F/TDF;   Drug: Placebo to match E/C/F/TAF
3 Active, not recruiting Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF
4 Active, not recruiting Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women (WAVES)
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: EVG/COBI/FTC/TDF;   Drug: RTV;   Drug: ATV;   Drug: FTC/TDF;   Drug: EVG/COBI/FTC/TDF Placebo;   Drug: RTV Placebo;   Drug: ATV Placebo;   Drug: FTC/TDF Placebo
5 Active, not recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: Stribild;   Drug: TVD;   Drug: NNRTI
6 Active, not recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: Stribild;   Drug: RTV;   Drug: TVD;   Drug: PI
7 Active, not recruiting Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV 1 Infected, Antiretroviral Treatment-Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: Placebo to match E/C/F/TAF;   Drug: Placebo to match E/C/F/TDF
8 Completed Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Intervention: Drug: EVG/COBI/FTC/TDF
9 Recruiting HIV Non-Occupational Post-Exposure Prophylaxis
Condition: Human Immunodeficiency Virus
Intervention: Drug: Coformulated Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)
10 Not yet recruiting An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
Condition: HIV-2 Infection
Intervention: Drug: Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks
11 Completed
Has Results
Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: Stribild;   Drug: Atripla
12 Active, not recruiting
Has Results
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: Stribild;   Drug: ATV/r + Truvada
13 Completed
Has Results
Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: Stribild;   Drug: Atripla
14 Active, not recruiting Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF, EFV/FTC/TDF, ritonavir + atazanavir + FTC/TDF, or cobicistat + atazanavir + FTC/TDF
15 Not yet recruiting Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.
Condition: HIV
Interventions: Drug: Tenofovir + emtricitabine (Truvada),+lopinavir/ritonavir (Kaletra);   Drug: elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil
16 Not yet recruiting Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy
Condition: HIV Infection
Intervention: Drug: Treatment simplification
17 Recruiting Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study
Conditions: Hepatitis C Infection;   HIV Infection
Intervention: Drug: Sofosbuvir, Ribavirin, and Stribild
18 Recruiting Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet
Condition: HIV
Intervention: Drug: (FDC) ELV/COBI/FTC/TDF
19 Active, not recruiting Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents
Conditions: Acquired Immune Deficiency Syndrome (AIDS);   HIV Infections
Intervention: Drug: E/C/F/TAF
20 Recruiting Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
Conditions: HIV;   HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: TAF;   Drug: Placebo to match TAF;   Drug: E/C/F/TAF;   Drug: Pre-existing ARV regimen;   Drug: ATV

Previous Page Studies Shown (1-20) Next Page (21-28) Show next page of results
Indicates status has not been verified in more than two years